NCT05283720 2026-03-03A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaGenmabPhase 2 Recruiting496 enrolled
NCT04775745 2026-02-13Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.Newave Pharmaceutical IncPhase 1 Recruiting60 enrolled
NCT05362773 2026-01-13A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesMacroGenicsPhase 1 Recruiting130 enrolled
NCT02924402 2024-11-13Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesXencor, Inc.Phase 1 Completed154 enrolled
NCT02175433 2024-11-01A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid MalignanciesAstellas Pharma IncPhase 1 Completed71 enrolled
NCT05645744 2024-07-22Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.Mustang BioTerminated3 enrolled
NCT01748721 2016-01-08MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaMorphotekPhase 1 Completed27 enrolled
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts